

PROVIDER QUICK POINTS

PROVIDER INFORMATION



August 21, 2018

Pharmacy Benefit Update – New Drug-Related Step Therapy (ST) with Quantity Limit (QL) Criteria: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors

Effective November 1, 2018, Blue Cross and Blue Shield of Minnesota (Blue Cross) will require ST for SGLT-2 Inhibitors under the pharmacy benefit plan.

The intent of the SGLT-2 Inhibitor ST program is to ensure appropriate selection of patients based on product labeling and/or clinical guidelines and/or clinical studies.

The ST requirement for SGLT-2 inhibitors is a patient who is concurrently receiving or has tried and failed insulin or a medication that is or contains metformin or a sulfonylurea. The step edit allows for continuation of therapy with the aforementioned medications when a patient is currently receiving the requested medication.

Please note: QLs are currently in place with SGLT-2 Inhibitors.

As stewards of healthcare expenditures for our subscribers, we are charged with ensuring the highest quality, evidence-based care. One method for doing so is through the ST process. The primary purpose is to ensure that evidence-based care is provided to our subscribers, driving quality, safety, and affordability.

SGLT-2 Inhibitor Step Therapy Targeted Drugs (Brands Only)	Quantity Limit (per 30 days)
Jardiance® (empagliflozin)	10 mg – 30 tablets 25 mg – 30 tablets
Segluromet™ (ertugliflozin / metformin)	2.5 mg/500 mg – 120 tablets 2.5 mg/1000 mg – 60 tablets 7.5 mg /500 mg – 60 tablets 7.5 mg/1000 mg – 60 tablets
Steglatro™ (ertugliflozin)	5 mg - 60 tablets 15 mg – 30 tablets
Synjardy® (empagliflozin / metformin)	5 mg /500 mg – 60 tablets 5 mg /1000 mg – 60 tablets 12.5 mg /500 mg – 60 tablets 12.5 mg /1000 mg – 60 tablets
Synjardy XR® (empagliflozin / metformin)	5 mg /1000 mg – 60 tablets 10 mg /1000 mg – 60 tablets 12.5 mg /1000 mg – 60 tablets 25 mg /1000 mg – 30 tablets

QP71-18

Distribution: Available on providers.bluecrossmn.com. <https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications>

Continued

Products impacted

This notice applies to the following Minnesota Health Care Programs:

- Blue Advantage Prepaid Medical Assistance Program (PMAP)
- Minnesota Senior Care Plus (MSC+)
- MinnesotaCare (MNCare)

The new Pharmacy ST program will be posted by October 1, 2018 and may be accessed using the Blue Cross provider link.

- Access **providers.bluecrossmn.com**
- Under Tools and Resources, select Medical policy, then acknowledge the Acceptance statement
- Select View All Active Policies
- Select Pharmacy Utilization Management Programs

CoverMyMeds prior authorization request service

Prescribers can submit ePA drug requests for Blue Cross subscribers who have pharmacy benefits through Blue Cross by either submitting a request through CoverMyMeds's (CMM) free web portal or by sending an electronic NCPDP file to Prime through an integrated Electronic Medical Record (EMR) system during the e-prescribing process.

- To access CMM, go to www.covermymeds.com
- The first time you use the portal to submit a PA, you will need to create a CMM account.
- For help using the CMM site select Support (top of the web page) to view FAQs, CMM physician training webinar offerings, and support options to help you get started.

Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.